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To the Editor: Aime and colleagues1 suggest that the Food
and Drug Administration (FDA) guidance on gadolinium-
based contrasting agents should lead to caution in the use of
lanthanum carbonate (FOSRENOL, Shire Pharmaceuticals,
Basingstoke, UK). The basis for their concern is that
gadolinium and lanthanum are similar physiochemically.
Gadolinium salts administered intravenously have known
toxicities and thus chelates are used to limit them.2 These are
administered usually at single intravenous doses of 0.1 mmol/
kg, leading to plasma gadolinium concentrations of up to
2.5 mmol/l (392.5 mg/l) at standard doses2 and 5 mmol/l
(785 mg/l) at double doses used for magnetic resonance
imaging angiography. The chelates are cleared primarily by
renal elimination. Thus, the half-life of gadolinium increases
from 1.96 h in healthy individuals to 5.61 anzd 9.18 h in patients
with chronic kidney disease stages 4 and 5, respectively.3
Prolonged systemic exposure increases the potential for
transmetalation and the release of free gadolinium. It is believed
that this free gadolinium forms insoluble complexes and
deposits in the skin and other organs.4
The exposure paradigms for gadolinium and lanthanum
are completely different. Gram doses of intravenous gadoli-
nium are 100% bioavailable, whereas oral lanthanum
carbonate has a bioavailability of 0.00127%.5 Plasma
lanthanum concentrations following long-term treatment
plateau at nanomolar levels of 2.5–9.7 nmol/l;6 approximately
500,000-fold lower than for gadolinium double dosing.
Furthermore, absorbed lanthanum is highly protein bound
(499.7%),5 resulting in free plasma lanthanum concentra-
tions in the pmol/l range. Rodent toxicity studies demon-
strate that skin concentrations of lanthanum are negligible
(oral gavage or intravenous dosing).7
There are no reports of nephrogenic systemic fibrosis asso-
ciated with lanthanum carbonate either in clinical trials (over
5000 patients) or in post-marketing surveillance (data on file).
The assumption that the risks of gadolinium can be
extrapolated to lanthanum on the basis of proximity in the
periodic table, rather than on pharmacokinetic, toxicologic,
and clinical evidence, is not warranted and scientifically
inappropriate.
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The biodistribution of lanthanum(III) complexes relies on
their speciation (that is, the distribution among chemical
species that provide coordination sites to the lanthanum(III)
ions). Among the huge number of biomolecules, the
speciation of lanthanum (III) complexes is determined by
their relative thermodynamic stabilities.1
The close analogy in the coordination chemistry of
lanthanum and gadolinium trivalent ions allows one to
anticipate that there would be analogies in the bio-
distribution of the two ions in living systems. However,
the administration route (oral or intravenous), the
quantities involved, and the chemical differences of the
forms that reach the blood (as highly thermodynamically
stable chelates in the case of gadolinium or speciated
among different biomolecules in the case of lanthanum
arising from the orally administered carbonate) generate
differences between the two protocols. Attention should be
invoked to consider the complex picture made of a number
of intercorrelated equilibria (that are analogous for the
two ions). On the basis of the tremendous output that
comes from the use of not sufficiently stable gadolinium
l e t t e r t o t h e e d i t o r http://www.kidney-international.org
& 2008 International Society of Nephrology
536 Kidney International (2008) 74, 536–538
